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Abstract: Pasteurella multocida produces a 146-kDa protein toxin (Pasteurella multocida 
toxin, PMT), which stimulates diverse cellular signal transduction pathways by activating 
heterotrimeric G proteins. PMT deamidates a conserved glutamine residue of the α-subunit 
of heterotrimeric G proteins that is essential for GTP-hydrolysis, thereby arresting the G 
protein in the active state. The toxin substrates are Gαq Gα13 and the Gαi-family proteins. 
Activation of these α-subunits causes stimulation of phospholipase Cβ, Rho-guanine 
nucleotide exchange factors or inhibition of adenylyl cyclase. This article provides the 
current knowledge on PMT concerning the structure-function analysis based on the crystal 
structure and recently elucidated molecular mode of action. Furthermore, the impact of 
PMT on cellular signaling is discussed. 
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1. Introduction 
Pasteurella multocida is a Gram negative opportunistic pathogenic bacterium living in the nasal, 
pharyngeal space of animals. Human infections occur usually by scratches and bites of domesticated 
animals (e.g., mainly cats and dogs). In addition, contact with salvia is sufficient for colonization of 
bacteria [1]. P. multocida is of particular importance in livestock management, especially of pigs. The 
infection of swine with P. multocida leads under special conditions to a atrophic rhinitis that was first 
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described by Franque in 1830 [2]. A main symptom in pigs is the loss of nasal turbinate bones leading 
to a twisted or shortened snout. The causative agent of atrophic rhinitis is a protein toxin produced by 
P. multocida (Pasteurella multocida toxin, PMT) [3,4]. 
2. Signal Transduction and Molecular Mechanism of PMT 
PMT stimulates a variety of signal transduction pathways (Figure 1). Phospholipase C (PLC) β, 
which is activated by Gαq, is stimulated to catalyze inositol trisphosphate production and Ca
2+ 
mobilization. In addition, the small GTPase RhoA is activated leading to stress fiber formation. 
Moreover, PMT is a strong mitogen in various cell lines. These effects are mainly due to the activation 
of heterotrimeric G proteins of the Gαq and Gα12/13 family. Furthermore, PMT activates Gαi thereby 
inhibiting adenylyl cyclase. Toxin-induced activation of heterotrimeric G proteins (e.g., Gi) releases 
Gβγ, which stimulates signaling pathways. 
Figure 1. Scheme of PMT-activated heterotrimeric G proteins and subsequent signaling 
pathways. PMT activates Gαi to inhibit adenylyl cyclase (AC). PMT-induced activation of 
Gα13 and Gαq stimulates Rho guanine nucleotide exchange factors (RhoGEF) leading to the 
activation of the low molecular mass GTPase RhoA. Moreover, activation of Gαq leads to 
stimulation of the Jak-STAT (Janus kinase, signal transducer and activator of transcription) 
pathway and the canonical Gαq effector phospholipase Cβ (PLCβ). By activation of the 
Gα-subunit, Gβγ is released from the heterotrimeric complex and mediates signaling via 
βγ-specific effectors, e.g., phosphoinositide-3-kinase (PI3K)γ. 
 
PMT was found to be an extremely potent mitogen for several cell types. Concentrations as low as 
1 to 2 pM stimulate DNA synthesis [5]. However, the toxin induces proliferation of osteoblasts even 
though one of the PMT-induced symptoms is the atrophy of nasal turbinate bones. The underlying 
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signaling pathways that govern PMT-induced proliferation are largely unknown. In HEK293 cells, 
PMT transactivates the epidermal growth factor (EGF) receptor in a Gαq-dependent manner. However, 
in cardiomyocytes the stimulation of the MAP kinase pathway occurs in an EGF receptor-independent 
manner [6,7]. Therefore, the PMT-induced pathways to enhance proliferation seem to be cell   
type specific. 
PMT enhances inositol trisphosphate production by activation of PLCβ, which in turn is stimulated 
by α-subunits of the Gαq/11 family [5,8]. Studies with Gαq and Gα11 gene deleted mouse embryonic 
fibroblasts (MEF) showed that PMT activates PLCβ only via Gαq but not via the closely related   
Gα11 [9]. This observation is noteworthy given that Gαq and Gα11 are 89% identical at the amino acid 
sequence level and Gαq-coupled receptors are generally found to activate Gα11 too. PMT distinguishes 
between both G proteins on the basis of the helical domain, which is inserted into the highly conserved 
GTPase domain. Replacement of helix αB of Gα11 by the Gαq helix enabled the toxin to activate the 
mutant Gα11 protein. However, introduction of helix αB of Gα11 into Gαq leads to a chimera, which is 
not activated by PMT [10]. 
Besides the stimulation of the prototypical Gαq effector PLCβ, the toxin stimulates the Jak-STAT 
(Janus kinase, signal transducer and activator of transcription) pathway in a Gαq-dependent manner 
[11]. PMT activates STAT1, 3 and 5 leading to altered gene expression, e.g. up-regulation of cancer-
associated cyclooxygenase (COX)-2 expression. 
RhoA is indirectly activated by PMT. The PMT-induced activation of the small GTPase RhoA is 
functionally connected with different families of heterotrimeric G proteins. It is known that the Gα12/13 
and Gαq families are capable of activating RhoA via guanine-nucleotide exchange factors (GEFs) like 
p115RhoGEF and p63RhoGEF, respectively [12,13]. Studies with Gαq/11-deficient MEF showed that 
PMT stimulates RhoA in a Gαq-independent manner [9]. Overexpression of Gα13 in Gα12/13-deficient 
MEF together with pharmacological inhibition of Gαq restored PMT-induced stimulation of RhoA 
[14]. However, comprehensive studies with Gαq/11- and Gα12/13-deficient MEF revealed that the toxin 
utilizes both families, Gα12/13 and Gαq, for stimulation of the small G protein RhoA. 
Beside Gαq and Gα12/13 the toxin activates Gαi. This leads to inhibition of the adenylyl cyclase [15]. 
PMT not only activates the α-subunit of heterotrimeric G proteins, but also stimulates Gβγ-pathways 
by release of Gβγ from G proteins. For example, PMT causes activation of phosphoinositide-3-kinase 
(PI3K)γ, which is a prototypical effector of Gβγ [16]. 
The recognition of Gαi as a target of PMT was one of the experimental milestones for elucidation of 
the molecular mechanism of PMT. Gαi is much easier to study than Gαq or Gα12/13, because 
recombinant expression in E. coli is possible. Furthermore, its GTPase function (e.g., GTP hydrolyzing 
activity) can be measured easily. 
To analyze the molecular mechanism of PMT, the toxin and Gαi2 were recombinantly co-expressed 
in E. coli. Studying Gαi2 from co-expression with active toxin showed inhibition of basal and RGS 
(regulator of G protein signaling)-stimulated GTPase activity. By tandem-mass spectrometry a 
difference in mass of one Dalton at glutamine-205 was detected, indicating a deamidation (Figure 2), 
which results in a glutamic acid residue [17]. This glutamine residue is conserved throughout the 
GTPase superfamily and is essential for the hydrolysis of the γ-phosphate of GTP thereby terminating 
the active state of the GTPase [18]. Deamidation of the pivotal glutamine residue results in an 
inhibition of the GTPase activity and arrests the G protein in a permanent active state. Functional Toxins 2010, 2                                       
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equivalent to glutamine-205 of Gαi2 is glutamine-209 of Gαq and Gα11. The deamidation of Gαq, which 
results in a change of the isoelectric point, could be demonstrated by faster migration in native gel 
electrophoresis. In agreement to the resistance of Gα11 towards PMT, no toxin-catalyzed deamidation 
of Gα11 was detectable [17]. 
Figure 2. (a) PMT deamidates the essential glutamine residue of the α-subunit of 
heterotrimeric G proteins, resulting in a glutamic acid residue. (b) Overview of Gαi1 
complexed with GDP/AlF4
- mimicking the transition state of the hydrolysis of the   
γ-phosphate of GTP. Two essential amino acid residues are highlighted: Arginine-178 in 
switch 1 (magenta) and glutamine-204 (corresponding to glutamine-205 in Gαi2) in switch 
2 (yellow). Both residues are involved in coordinating the γ-phosphate (here AlF4
-) and a 
water nucleophile (blue sphere). PMT deamidates the glutamine residue in switch 2. 
Therefore, hydrolysis of the γ-phosphate of GTP is not possible anymore and the G protein 
is arrested in the active state. This image was generated using PyMol and PDB data file 
1GFI.  
PMT activates heterotrimeric G proteins independent of any receptor interaction. A chimera of a 
GPCR (α1-adrenoceptor) with Gαq as well as a deletion mutant of Gαq, incapable of interacting with 
GPCRs is stimulated by PMT [19]. Accordingly, ADP-ribosylation of Gαi by pertussis toxin, which 
uncouples the G protein from GPCRs, has no impact on subsequent PMT-induced activation. On the 
other hand pre-treatment of Gi with PMT inhibits pertussis toxin-induced ADP-ribosylation [15]. This 
is explained by the fact that pertussis toxin modifies the inactive, heterotrimeric Gi complex [20]. 
Therefore, activation and dissociation of the heterotrimeric G protein by PMT leads to insensitivity 
towards pertussis toxin. 
   
Gα
glutamine
PMT
C=O
NH2
glutamic acid NH3 H2O
Gα
C=O
OH
A
B
switch2
switch1
R178
Q204
GDP AlF4
‐Toxins 2010, 2                                       
 
 
209
3. Structure 
PMT is a 146-kDa protein toxin, encompassing 1,285 amino acid residues [21]. It belongs to a 
family of dermonecrotic toxins, including the cytotoxic necrotizing factors (CNF1-3) from Escherichia 
coli and Yersinia pseudotuberculosis (CNFy) and dermonecrotic toxin (DNT) from Bordetella 
pertussis and B. bronchiseptica and PMT. These toxins share significant sequence homology in their 
N-terminal parts. In CNFs and DNT, the N-terminus is important for receptor binding and 
translocation to the cytosol [22,23]. Therefore, the homology between PMT and CNFs / DNT suggests 
a similar function of the N-terminal part and overall a similar domain structure with a receptor binding 
and translocation domain in the N-terminus and a catalytic domain in the C-terminus.  
In line with this model, fragments of PMT that lack the receptor or proposed translocation domains 
have no toxic effects, when applied to culture medium or admistered to animals [24,25]. However, a 
C-terminal fragment without receptor binding and translocation domain, consisting of amino acid 581 
to 1285, has the identical effects as full-length toxin if directly introduced into mammalian cells by 
electroporation [23,26]. Recently, this part was crystallized (Figure 3) [27]. The C-terminus of PMT 
consists of three domains C1, C2 and C3 with a so-called Trojan horse-like overall structure. The C1 
domain (residues 569–719) has structural similarities with another bacterial protein toxin, Clostridium 
diffcile toxin B. In toxin B this domain targets the toxin to the intracellular site of the plasma 
membrane [28]. An identical function is suggested for the PMT C1 domain [27]. The C2 domain 
(residues 720–1104) is similar to a folylpolyglutamate synthetase but its function remains unknown. 
Most important is the C3 domain (residues 1105–1285) harboring the catalytic activity of the toxin. 
Figure 3. Domain architecture of the C-terminal part of PMT. The crystal structure of the 
C-terminal part of PMT (amino acids 575–1285) revealed 3 domains C1, C2 and C3. The 
C1 domain (magenta) has similarities with a domain of Clostridium difficile toxin B and 
targets the toxin to the inner part of the plasma membrane. The function of the C2 domain 
(green) is unknown. The C3 domain provides a catalytic cleft (arrow) and harbors the 
biological activity of the toxin. This image was generated using PyMol and PDB data file 
2EBF. 
C1
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The primary amino acid sequence of the C3 domain showed no homology to any other protein but 
the crystal structure revealed first insights into the possible function of PMT. Crystallization of   
wt-PMT leads to a structure harboring a disulfide bond between cysteine-1159 and cysteine-1165. 
Cleavage of this disulfide bond by mutation of cysteine-1159 to serine leads to reorientation of 
cysteine-1165 (Figure 3 and 4). The re-orientated cysteine-1165, together with histidine-1205 and 
aspartic acid-1220, forms a topology that resembles a catalytic triad, suggesting an essential role for 
these residues in the activity of PMT [27]. Localization of the biological activity in the very   
C-terminus was supported by the finding that the ectopical expression of the C3 domain in mammalian 
cells leads to identical effects as the expression of the full-length toxin [29]. 
Figure 4. (a) Structure of the C-terminal C3 domain of PMT. This domain harbors the 
biological activity of the toxin with the catalytic triad (highlighted in red) cysteine-1165, 
histidine-1205 and aspartic acid-1220. Interestingly, cysteine-1165 of the triad is normally 
closed by a disulfide bridge with cysteine at position 1159 (green). Here the structure of a 
mutant toxin (C1159S), which releases the catalytic active cysteine-1165 from the disulfide 
bond, is shown. (b) Catalytic triads of thiol proteases (papain), transglutaminases (Factor 
XIII) and deamidases (PMT, CNF1). Catalytic active histidines were superimposed. This 
image was generated using PyMol and PDB data file 2EBF (PMT), 1HQ0 (CNF1), 1POP 
(papain) and 1GGT (Factor XIII). 
As already described, PMT acts as a deamidase to constitutively activate heterotrimeric G proteins. 
The same mechanism is utilized by CNFs, which deamidate the essential glutamine in low molecular 
mass GTPases as RhoA, Rac or Cdc42 [30,31]. In addition, DNT deamidates Rho proteins at 
glutamine-61(63) like CNF. Moreover, DNT can act as a transglutaminase on Rho proteins [32,33]. 
PMT/ CNF/ papain/ Factor XIII
H1205/ H881 / H159 / H373
D1220/ N175 / D396
C1165/ C25 / C314
V833
C866
H1205
D1220
C1165
1159
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PMT has sequence similarity with CNF and DNT in the N-terminal binding and translocation domains. 
In contrast, PMT has no obvious structural similarity with CNFs or DNT at the C-terminal catalytic 
domain [27,34]. Even the topology of the catalytic center is different (Figure 4B). PMT and CNF share 
the catalytic amino acid residues histidine and cysteine. The third catalytic amino acid residues in the 
case of PMT is aspartic acid and in the case of CNF valine. 
However, the catalytic triads of PMT and papain match perfectly, therefore it was suggested that 
PMT acts as a cysteine protease. Functional and structural comparison of deamidases and thiol 
proteases with transglutaminases explains this divergence. From the type of chemical reaction that they 
catalyze, transglutaminases, which replace the NH2-group of the amide of a glutamine by another 
amine residue, are closely related to deamidases, which change the amide to a carboxylate by using 
H20 as co-substrate. Furthermore, thiol proteases like papain catalyze the reverse reaction of 
transglutaminases. Due to this reason, it is not surprising that the catalytic triad of PMT matches the 
catalytic triads of thiol proteases or transglutaminases [35,36]. For example, the catalytic triad   
(Cys-His-Asp) of the transglutaminases factor XIII perfectly matches the position of the catalytic triad 
of PMT. 
4. Toxin Uptake 
To date, our knowledge about the cellular up-take of PMT is rather limited. It is generally accepted 
that receptor-mediated endocytosis is essential for PMT uptake by mammalian cells. Uptake could be 
competed with mixed gangliosides, therefore the receptor was suggested to belong to this class [37]. 
Release of the toxin into the cytosol from early endosome is driven by acidification; consequently 
bafilomycin A1, an inhibitor of the vacuolar ATPases, inhibits intoxication [38]. Accordingly, 
mimicking endosomal acidification by exposing toxin-bound cells to acidic medium leads to direct 
translocation of PMT to the cytosol. It is suggested that acidification induces conformational changes 
of PMT allowing exposure of two hydrophobic helices. The actual uptake model suggests that these 
helices are introduced into the endosomal membrane [39]. The precise mechanism of the translocation 
of PMT into the cytosol remains to be elucidated. 
5. Conclusions 
For a long time the mechanism of PMT-mediated activation of heterotrimeric G-proteins remained 
enigmatic. The elucidation of the crystal structure of the toxin and recognition of Gαi as an additional 
toxin substrate were pivotal to clarify the molecular mechanism of PMT. The toxin deamidates a 
glutamine of the α-subunits of heterotrimeric G-proteins. This glutamine is essential for hydrolyzing 
GTP. Therefore, the deamidation leads to a permanent active G protein. PMT acts on different families 
of heterotrimeric G-proteins (Gαi, Gαq and Gα12/13), even though it surprisingly distinguishes between 
the closely related Gαq and Gα11. In addition to Gα-signaling, PMT induces signaling by Gβγ subunits, 
which are released upon activation of heterotrimeric G proteins. 
Interestingly, PMT is one of the strongest mitogens known. In addition, it is known that frequent 
somatic mutations in the gene Gnaq, encoding Gαq, are found in melanoma of the uvea (46%) and in 
blue naevi (83%). These mutations result in change of glutamine-209 in a manner similar to the Toxins 2010, 2                                       
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constitutive activation, which is caused by PMT [40]. Therefore, it remains to be clarified whether the 
toxin plays a role in cancer development. 
Acknowledgements 
Studies from the laboratory of the authors reported in this review were supported by the Deutsche 
Forschungsgemeinschaft (SFB 746). 
References  
1. Kristinsson,  G.  Pasteurella multocida infections. Pediatr. Rev. 2007, 28, 472–473. 
2.    Franque, L.W. Was ist die Schnueffelkrankheit der Schweine? Teutsche Zeitschrift fuer die 
gesammte Thierheilkunde 1830, 1, 75–77. 
3.   Dominick, M.A.; Rimler, R.B. Turbinate atrophy in gnotobiotic pigs intranasally inoculated with 
protein toxin isolated from type D Pasteurella multocida. Am. J. Vet. Res. 1986, 47, 1532–1536. 
4.    Lax, A.J.; Chanter, N. Cloning of the toxin gene from Pasteurella multocida and its role in 
atrophic rhinitis. J. Gen. Microbiol. 1990, 136, 81–87. 
5.   Rozengurt, E.; Higgins, T.; Chanter, N.; Lax, A.J.; Staddon, J.M. Pasteurella multocida toxin: 
Potent mitogen for cultured fibroblasts. Proc. Natl. Acad. Sci. USA 1990, 87, 123–127. 
6.   Seo, B.; Choy, E.W.; Maudsley, W.E.; Miller, W.E.; Wilson, B.A.; Luttrell, L.M. Pasteurella 
multocida toxin stimulates mitogen-activated protein kinase via Gq/11-dependent transactivation of 
the epidermal growth factor receptor. J. Biol. Chem. 2000, 275, 2239–2245. 
7.    Sabri, A.; Wilson, B.A.; Steinberg, S.F. Dual actions of the Galpha(q) agonist Pasteurella 
multocida toxin to promote cardiomyocyte hypertrophy and enhance apoptosis susceptibility. 
Circ. Res. 2002, 90, 850–857. 
8.    Wilson, B.A.; Zhu, X.; Ho, M.; Lu, L. Pasteurella multocida toxin activates the inositol 
triphosphate signaling pathway in Xenopus oocytes via Gqa-coupled phospholipase C-b1. J. Biol. 
Chem. 1997, 272, 1268–1275. 
9.    Zywietz, A.; Gohla, A.; Schmelz, M.; Schultz, G.; Offermanns, S. Pleiotropic effects of 
Pasteurella multocida toxin are mediated by Gq-dependent and -independent mechanisms. 
Involvement of Gq but not G11. J. Biol. Chem. 2001, 276, 3840–3845. 
10.  Orth, J.H.; Lang, S.; Aktories, K. Action of Pasteurella multocida toxin depends on the helical 
domain of Galphaq. J. Biol. Chem. 2004, 279, 34150–34155. 
11. Orth, J.H.; Aktories, K.; Kubatzky, K.F. Modulation of host cell gene expression through 
activation of STAT transcription factors by Pasteurella multocida toxin. J. Biol. Chem. 2007, 282, 
3050–3057. 
12.   Kozasa, T.; Jiang, X.; Hart, M.J.; Sternweis, P.M.; Singer, W.D.; Gilman, A.G.; Bollag, G.; 
Sternweis, P.C. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 
1998, 280, 2109–2111. 
13.  Lutz, S.; Freichel-Blomquist, A.; Yang, Y.; Rumenapp, U.; Jakobs, K.H.; Schmidt, M.; Wieland, 
T. The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled 
receptor signaling and RhoA. J. Biol. Chem. 2005, 280, 11134–11139. Toxins 2010, 2                                       
 
 
213
14.  Orth, J.H.; Lang, S.; Taniguchi, M.; Aktories, K. Pasteurella multocida toxin-induced activation 
of RhoA is mediated via two families of G{alpha} proteins, G{alpha}q and G{alpha}12/13. J. 
Biol. Chem. 2005, 280, 36701–36707. 
15.  Orth, J.H.; Fester, I.; Preuss, I.; Agnoletto, L.; Wilson, B.A.; Aktories, K. Activation of Galphai 
and subsequent uncoupling of receptor-Galphai signaling by Pasteurella multocida toxin. J. Biol. 
Chem. 2008, 283, 23288–23294. 
16.  Preuss, I.; Kurig, B.; Nurnberg, B.; Orth, J.H.; Aktories, K. Pasteurella multocida toxin activates 
Gbetagamma dimers of heterotrimeric G proteins. Cell. Signal. 2009, 21, 551–558. 
17.  Orth, J.H.; Preuss, I.; Fester, I.; Schlosser, A.; Wilson, B.A.; Aktories, K. Pasteurella multocida 
toxin activation of heterotrimeric G proteins by deamidation. Proc. Natl. Acad. Sci. USA 2009, 
106, 7179–7184. 
18.  Tesmer, J.J.; Berman, D.M.; Gilman, A.G.; Sprang, S.R. Structure of RGS4 bound to AlF4--
activated G(i alpha1): stabilization of the transition state for GTP hydrolysis. Cell  1997,  89,  
251–261. 
19.  Orth, J.H.; Lang, S.; Preuss, I.; Milligan, G.; Aktories, K. Action of Pasteurella multocida toxin 
on Galpha(q) is persistent and independent of interaction with G-protein-coupled receptors. Cell. 
Signal. 2007, 19, 2174–2182. 
20.  Katada, T.; Oinuma, M.; Ui, M. Two guanine nucleotide-binding proteins in rat brain serving as 
the specific substrate of islet-activating protein, pertussis toxin. Interaction of the alpha-subunits 
with beta gamma-subunits in development of their biological activities. J. Biol. Chem. 1986, 261, 
8182–8191. 
21.  Petersen, S.K. The complete nucleotide sequence of the Pasteurella multocida toxin gene and 
evidence for a transcriptional repressor, TxaR. Mol. Microbiol. 1990, 4, 821–830. 
22.  Lemichez, E.; Flatau, G.; Bruzzone, M.; Boquet, P.; Gauthier, M. Molecular localization of the 
Escherichia coli cytotoxic necrotizing  factor CNF1 cell-binding and catalytic domains. Mol. 
Microbiol. 1997, 24, 1061–1070. 
23.  Pullinger, G.D.; Sowdhamini, R.; Lax, A.J. Localization of functional domains of the mitogenic 
toxin of Pasteurella multocida. Infect. Immun. 2001, 69, 7839–7850. 
24.  Nakai, T.; Kume, K. Purification of three fragments of the dermonecrotic toxin from Pasteurella 
multocida. Res Vet. Sci 1987, 42, 232–237. 
25.  Wilson, B.A.; Ponferrada, V.G.; Vallance, J.E.; Ho, M.F. Localization of the intracellular activity 
domain of Pasteurella multocida toxin to the N terminus. Infect. Immunity 1999, 67, 80–87. 
26.  Busch, C.; Orth, J.; Djouder, N.; Aktories, K. Biological activity of a C-terminal fragment of 
Pasteurella multocida toxin. Infect. Immun. 2001, 69, 3628–3634. 
27.   Kitadokoro, K.; Kamitani, S.; Miyazawa, M.; Hanajima-Ozawa, M.; Fukui, A.; Miyake, M.; 
Horiguchi, Y. Crystal structures reveal a thiol protease-like catalytic triad in the C-terminal region 
of Pasteurella multocida toxin. Proc. Natl. Acad. Sci. USA 2007, 104, 5139–5144. 
28.  Reinert, D.J.; Jank, T.; Aktories, K.; Schulz, G.E. Structural Basis for the Function of Clostridium 
difficile Toxin B. J. Mol. Biol. 2005, 351, 973–981. 
29.   Aminova, L.R.; Luo, S.; Bannai, Y.; Ho, M.; Wilson, B.A. The C3 domain of Pasteurella 
multocida toxin is the minimal domain responsible for activation of Gq-dependent calcium and 
mitogenic signaling. Protein Sci 2008, 17, 1–5. Toxins 2010, 2                                       
 
 
214
30.  Schmidt, G.; Sehr, P.; Wilm, M.; Selzer, J.; Mann, M.; Aktories, K. Gln63 of Rho is deamidated 
by Escherichia coli cytotoxic necrotizing factor 1. Nature 1997, 387, 725–729. 
31.  Flatau, G.; Lemichez, E.; Gauthier, M.; Chardin, P.; Paris, S.; Fiorentini, C.; Boquet, P. Toxin-
induced activation of the G protein p21 Rho by deamidation of glutamine. Nature 1997, 387,  
729–733. 
32.  Horiguchi, Y.; Inoue, N.; Masuda, M.; Kashimoto, T.; Katahira, J.; Sugimoto, N.; Matsuda, M. 
Bordetella bronchiseptica dermonecrotizing toxin induces reorganization of actin stress fibers 
through deamidation of Gln-63 of the GTP-binding protein Rho. Proc. Natl. Acad. Sci. USA 1997, 
94, 11623–11626. 
33.    Masuda, M.; Betancourt, L.; Matsuzawa, T.; Kashimoto, T.; Takao, T.; Shimonishi, Y.; 
Horiguchi, Y. Activation of Rho through a cross-link with polyamines catalyzed by Bordetella 
dermonecrotizing toxin. EMBO J. 2000, 19, 521–530. 
34.  Buetow, L.; Flatau, G.; Chiu, K.; Boquet, P.; Ghosh, P. Structure of the Rho-activating domain of 
Escherichia coli cytotoxic necrotizing factor 1. Nature Struct. Biol. 2001, 8, 584–588. 
35.    Pedersen, L.C.; Yee, V.C.; Bishop, P.D.; Trong, I.L.; Teller, D.C.; Stenkamp, R.E. 
Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules. 
Protein Sci. 1994, 3, 1131–1135. 
36.  Kashiwagi, T.; Yokoyama, K.; Ishikawa, K.; Ono, K.; Ejima, D.; Matsui, H.; Suzuki, E. Crystal 
structure of microbial transglutaminase from Streptoverticillium mobaraense. J. Biol. Chem. 2002, 
277, 44252–44260. 
37.  Pettit, R.K.; Ackermann, M.R.; Rimler, R.B. Receptor-mediated binding of Pasteurella multocida 
dermonecrotic toxin to canine osteosarcoma and monkey kidney (vero) cells. Labor. Invest. 1993, 
69, 94–100. 
38.  Staddon, J.M.; Barker, C.J.; Murphy, A.C.; Chanter, N.; Lax, A.J.; Michell, R.H.; Rozengurt, E. 
Pasteurella multocida toxin, a potent mitogen, increases inositol 1,4,5-triphosphate and mobilizes 
Ca
2+ in swiss 3T3 cells. J. Biol. Chem. 1991, 266, 4840–4847. 
39.   Baldwin, M.R.; Lakey, J.H.; Lax, A.J. Identification and characterization of the Pasteurella 
multocida toxin translocation domain. Mol. Microbiol. 2004, 54, 239–250. 
40.   Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O'Brien, J.M.; 
Simpson, E.M.; Barsh, G.S.; Bastian, B.C. Frequent somatic mutations of GNAQ in uveal 
melanoma and blue naevi. Nature 2008, 457, 599–602. 
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 